Table 1.
Joinpoint analyses (1975–2006)b | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Trend 1 | Trend 2 | Trend 3 | Trend 4 | Trend 5 | AAPCf | |||||||
Sex/cancer site or type | Years | APCe | Years | APCe | Years | APCe | Years | APCe | Years | APCe | 1997–2006 | 2002–2006 |
All sitesc | ||||||||||||
Both sexes | 1975–1989 | 1.2g | 1989–1992 | 2.8g | 1992–1995 | −2.4 | 1995–1999 | 1.0 | 1999–2006 | −1.1g | −0.6h | −1.1h |
(Delay-adjusted) | 1975–1989 | 1.2g | 1989–1992 | 2.8 | 1992–1995 | −2.4 | 1995–1999 | 0.9 | 1999–2006 | −0.7g | −0.4h | −0.7h |
Males | 1975–1989 | 1.3g | 1989–1992 | 5.1g | 1992–1995 | −4.8g | 1995–2001 | 0.3 | 2001–2006 | −1.9g | −0.9h | −1.9h |
(Delay-adjusted) | 1975–1989 | 1.3g | 1989–1992 | 5.2g | 1992–1995 | −4.9g | 1995–2000 | 0.5 | 2000–2006 | −1.3g | −0.7h | −1.3h |
Females | 1975–1979 | −0.3 | 1979–1987 | 1.6g | 1987–1995 | 0.1 | 1995–1998 | 1.5 | 1998–2006 | −0.8g | −0.5h | −0.8h |
(Delay-adjusted) | 1975–1979 | −0.3 | 1979–1987 | 1.6g | 1987–1995 | 0.1 | 1995–1998 | 1.4 | 1998–2006 | −0.5g | −0.3 | −0.5h |
Top 15 cancers for malesd | ||||||||||||
Prostate | 1975–1988 | 2.6g | 1988–1992 | 16.4g | 1992–1995 | −11.4g | 1995–2001 | 1.8 | 2001–2006 | −3.4g | −1.1 | −3.4h |
(Delay-adjusted) | 1975–1988 | 2.6g | 1988–1992 | 16.5g | 1992–1995 | −11.7g | 1995–2000 | 2.4 | 2000–2006 | −2.4g | −0.8 | −2.4h |
Lung and bronchus | 1975–1982 | 1.4g | 1982–1991 | −0.4 | 1991–2006 | −1.9g | −1.9h | −1.9h | ||||
(Delay-adjusted) | 1975–1982 | 1.4g | 1982–1991 | −0.4 | 1991–2006 | −1.8g | −1.8h | −1.8h | ||||
Colon and rectum | 1975–1986 | 1.1g | 1986–1995 | −2.1g | 1995–1998 | 1.1 | 1998–2004 | −2.6g | 2004–2006 | −5.7g | −2.9h | −4.2h |
(Delay-adjusted) | 1975–1985 | 1.1g | 1985–1991 | −1.2g | 1991–1995 | −3.2g | 1995–1998 | 2.1 | 1998–2006 | −3.0g | −2.5h | −3.0h |
Urinary bladder | 1975–1987 | 1.0g | 1987–1996 | −0.5 | 1996–1999 | 1.8 | 1999–2006 | −0.8g | −0.2 | −0.8h | ||
(Delay-adjusted) | 1975–1987 | 0.9g | 1987–2006 | 0.0 | 0.0 | 0.0 | ||||||
Melanoma of the skin | 1975–1986 | 5.5g | 1986–2006 | 2.9g | 2.9h | 2.9h | ||||||
(Delay-adjusted) | 1975–1986 | 5.4g | 1986–2006 | 3.1g | 3.1h | 3.1h | ||||||
Non-Hodgkin lymphoma | 1975–1991 | 4.3g | 1991–2006 | 0.1 | 0.1 | 0.1 | ||||||
(Delay-adjusted) | 1975–1991 | 4.2g | 1991–2006 | 0.3 | 0.3 | 0.3 | ||||||
Kidney and renal pelvis | 1975–2006 | 1.7g | 1.7h | 1.7h | ||||||||
(Delay-adjusted) | 1975–2006 | 1.8g | 1.8h | 1.8h | ||||||||
Leukemia | 1975–2004 | −0.1 | 2004–2006 | −6.6 | −1.6h | −3.4 | ||||||
(Delay-adjusted) | 1975–2006 | 0.1g | 0.1h | 0.1h | ||||||||
Oral cavity and pharynx | 1975–1983 | −0.2 | 1983–2006 | −1.4g | −1.4h | −1.4h | ||||||
(Delay-adjusted) | 1975–2006 | −1.2g | −1.2h | −1.2h | ||||||||
Pancreas | 1975–1993 | −0.9g | 1993–2006 | 0.3 | 0.3 | 0.3 | ||||||
(Delay-adjusted) | 1975–1981 | −1.8g | 1981–1985 | 1.1 | 1985–1990 | −2.1 | 1990–2003 | 0.1 | 2003–2006 | 2.5 | 0.9 | 1.9 |
Stomach | 1975–1988 | −1.2g | 1988–2006 | −2.0g | −2.0h | −2.0h | ||||||
(Delay-adjusted) | 1975–1988 | −1.2g | 1988–2006 | −2.0g | −2.0h | −2.0h | ||||||
Liver and intrahepatic bile duct | 1975–1986 | 2.1g | 1986–1996 | 4.9g | 1996–2006 | 2.6g | 2.6h | 2.6h | ||||
(Delay-adjusted) | 1975–2006 | 3.6g | 3.6h | 3.6h | ||||||||
Esophagus | 1975–2006 | 0.7g | 0.7h | 0.7h | ||||||||
(Delay-adjusted) | 1975–2006 | 0.7g | 0.7h | 0.7h | ||||||||
Brain and other nervous system | 1975–1991 | 1.1g | 1991–2006 | −0.7g | −0.7h | −0.7h | ||||||
(Delay-adjusted) | 1975–1991 | 1.0g | 1991–2006 | −0.5g | −0.5h | −0.5h | ||||||
Myeloma | 1975–2002 | 0.8g | 2002–2006 | −3.0 | −0.9 | −3.0 | ||||||
(Delay-adjusted) | 1975–2006 | 0.7g | 0.7h | 0.7h | ||||||||
Top 15 cancers for femalesd | ||||||||||||
Breast | 1975–1980 | −0.5 | 1980–1987 | 4.0g | 1987–1994 | −0.2 | 1994–1999 | 1.6g | 1999–2006 | −2.2g | −1.3h | −2.2h |
(Delay-adjusted) | 1975–1980 | −0.5 | 1980–1987 | 4.0g | 1987–1994 | −0.1 | 1994–1999 | 1.6g | 1999–2006 | −2.0g | −1.2h | −2.0h |
Lung and bronchus | 1975–1982 | 5.5g | 1982–1990 | 3.5g | 1990–1998 | 1.0g | 1998–2006 | −0.1 | 0.0 | −0.1 | ||
(Delay-adjusted) | 1975–1982 | 5.6g | 1982–1991 | 3.4g | 1991–2006 | 0.4g | 0.4h | 0.4h | ||||
Colon and rectum | 1975–1985 | 0.3 | 1985–1995 | −1.9g | 1995–1998 | 2.0 | 1998–2006 | −2.4g | −1.9h | −2.4h | ||
(Delay-adjusted) | 1975–1985 | 0.3 | 1985–1995 | −1.8g | 1995–1998 | 1.9 | 1998–2006 | −2.2g | −1.7h | −2.2h | ||
Corpus and uterus, NOS | 1975–1979 | −6.0g | 1979–1988 | −1.7g | 1988–1997 | 0.7g | 1997–2006 | −0.6g | −0.6h | −0.6h | ||
(Delay-adjusted) | 1975–1979 | −6.0g | 1979–1988 | −1.7g | 1988–1997 | 0.7g | 1997–2006 | −0.5g | −0.5h | −0.5h | ||
Melanoma of the skin | 1975–1980 | 5.6g | 1980–2006 | 2.4g | 2.4h | 2.4h | ||||||
(Delay-adjusted) | 1975–1981 | 5.7g | 1981–1993 | 1.9g | 1993–2006 | 3.0g | 3.0h | 3.0h | ||||
Non-Hodgkin lymphoma | 1975–1990 | 2.8g | 1990–2004 | 1.2g | 2004–2006 | −2.5 | 0.3 | −0.7 | ||||
(Delay-adjusted) | 1975–1990 | 2.9g | 1990–2006 | 1.1g | 1.1h | 1.1h | ||||||
Thyroid | 1975–1977 | 6.5 | 1977–1980 | −5.3 | 1980–1995 | 2.3g | 1995–2006 | 6.0g | 6.0h | 6.0h | ||
(Delay-adjusted) | 1975–1977 | 6.5 | 1977–1980 | −5.3 | 1980–1995 | 2.3g | 1995–2006 | 6.3g | 6.3h | 6.3h | ||
Ovaryc | 1975–1985 | 0.1 | 1985–2001 | −0.7g | 2001–2006 | −2.6g | −1.8h | −2.6h | ||||
(Delay-adjusted)c | 1975–1985 | 0.1 | 1985–2001 | −0.7g | 2001–2006 | −2.1g | −1.5h | −2.1h | ||||
Pancreas | 1975–1984 | 1.5g | 1984–1995 | −0.6 | 1995–2006 | 0.6g | 0.6h | 0.6h | ||||
(Delay-adjusted) | 1975–1984 | 1.3g | 1984–2000 | −0.3 | 2000–2006 | 1.7g | 1.0h | 1.7h | ||||
Leukemia | 1975–2006 | 0.0 | 0.0 | 0.0 | ||||||||
(Delay-adjusted) | 1975–2006 | 0.3g | 0.3h | 0.3h | ||||||||
Kidney and renal pelvis | 1975–2006 | 2.3g | 2.3h | 2.3h | ||||||||
(Delay-adjusted) | 1975–2006 | 2.4g | 2.4h | 2.4h | ||||||||
Urinary bladder | 1975–2003 | 0.2g | 2003–2006 | −2.3 | −0.6 | −1.7 | ||||||
(Delay-adjusted) | 1975–2006 | 0.2g | 0.2h | 0.2h | ||||||||
Cervix uteri | 1975–1981 | −4.6g | 1981–1996 | −1.1g | 1996–2006 | −3.6g | −3.6h | −3.6h | ||||
(Delay-adjusted) | 1975–1981 | −4.6g | 1981–1996 | −1.1g | 1996–2006 | −3.5g | −3.5h | −3.5h | ||||
Oral cavity and pharynx | 1975–1980 | 2.6g | 1980–2006 | −1.0g | −1.0h | −1.0h | ||||||
(Delay-adjusted) | 1975–1980 | 2.5 | 1980–2006 | −0.9g | −0.9h | −0.9h | ||||||
Brain and other nervous system | 1975–1987 | 1.6g | 1987–2006 | −0.3 | −0.3 | −0.3 | ||||||
(Delay-adjusted) | 1975–1987 | 1.6g | 1987–2006 | −0.1 | −0.1 | −0.1 |
SEER: Surveillance, Epidemiology and End Results; APC: annual percent change; NOS: not otherwise specified.
Source: SEER 9 areas covering about 10% of the U.S. population (Connecticut, Hawaii, Iowa, Utah, and New Mexico, and the metropolitan areas of San Francisco, Detroit, Atlanta, and Seattle-Puget Sound).
Joinpoint analyses with up to four joinpoints are based on rates per 100,000 persons and were age-adjusted to the 2000 U.S. standard population (19 age groups Census p25–1130). Joinpoint (JP) Regression Program, Version 3.3.1. April 2008, National Cancer Institute.
All sites excludes myelodysplastic syndromes and borderline tumors; ovary excludes borderline tumors.
The top 15 cancers were selected based on the sex-specific age-adjusted incidence rates for 2002–2006 for all races combined and are listed in rank order.
APC is based on rates that were age-adjusted to the 2000 U.S. standard population (19 age groups Census p25–1130).
The AAPC is the Average Annual Percent Change and is a weighted average of the APCs calculated by Joinpoint.
APC is statistically significantly different from zero (2-sided P < .05).
AAPC is statistically significantly different from zero.